NCT01466855

A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma

A Pilot Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Children's Hospital Medical Center, Cincinnati · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

This study will test if giving topotecan directly into the blood vessel of the eye will improve the treatment of retinoblastoma. This method is referred to as "selective intra-ophthalmic artery chemotherapy" (SIOAC). The goals of this study are: * To find out if topotecan is an effective treatment for retinoblastoma when delivered directly to the ophthalmic artery (SIOAC delivery) * To find out what kind of effects (good and bad) can be expected when topotecan is given by SIOAC * To assess visual pathway function before and after the study therapy * To learn more about the pharmacology (how your body handles the drug) of topotecan when delivered directly to the ophthalmic artery

Conditions

• Retinoblastoma

Interventions

Type	Name	Description
DRUG	Intra-Ophthalmic Artery Topotecan Infusion	Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.

Timeline

• Start date: 2011-10-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2011-11-08
• Last updated: 2020-09-14

Locations

1 site across 1 country: United States